Erlotinib effective and with fewer side-effects after first-line treatment, phase III trial shows

The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show.

Read the whole article on Science Daily

More from Science Daily